Friday, February 20, 2009


SoCal Firms Waiting For IPO Market, Still
Think the IPO market is dead? Apparently, firms are still hoping the market will open up for initial public offerings, with 57 companies nationwide still in registration for an IPO, as of the end of December. According to numbers released recently by Ernst & Young, California led the nation in terms of companies in registration for an IPO, with eight companies seeking to raise $855 million on the markets. At least three Southern California technology firms -- Thousand Oaks-based Nexsan, Irvine-b (More info...)
posted on Friday, February 20, 2009(Full story)

MySpace Pulls Plug On Flektor
Flektor, the online web slideshow and photo and video sharing site owned by Fox Interactive Media, appears to have completely disappeared as of this morning. A source close to the firm said that the service was being completely shut down today, including the servers, videos, polls, and more. The service's web site now goes directly to the MySpace home page. Flektor had been acquired by Fox Interactive Media in May of 2007.
posted on Friday, February 20, 2009(Full story)

Mogreet, Mobile-XL Partner
Los Angeles-based wireless software publisher Mobile-XL reported Thursday that it is partnering with Venice-based mobile video messaging firm Mogreet. According to Mobile-XL, both companies have committed resources toward developing a mobile messaging platform. Mogreet operates a mobile greeting card service which sends short video snippets to mobile phones. Mobile-XL develops mobile browser software and information services. Mobile-XL noted that the two companies plan to unveil the collaboratio (More info...)
posted on Friday, February 20, 2009(Full story)

La Jolla Pharmaceuticals Lays Off Staff, Looks To Sell Firm
San Diego-based La Jolla Pharmaceutical Company has laid of a "substantial" number of the firm's personnel, and is looking to either shut down the business or sell the company, the firm said Thursday, after a failure of the firm's Phase 3 trials. According to the firm, the "substantial reduction in personnel" comes after negative results of the firm's Riquent Phase 3 interim efficacy analysis. Riquent was La Jolla's lead compound, and was targeted at treating lupus renal disease by preventing o (More info...)
posted on Friday, February 20, 2009(Full story)